Reumatologia Clinica最新文献

{"title":"Some aspects of body thermoregulation, environmental temperature and vascular hypothesis in systemic sclerosis patients","authors":"Francisco Javier Olmedo Garzón","doi":"10.1016/j.reuma.2025.501894","DOIUrl":"10.1016/j.reuma.2025.501894","url":null,"abstract":"<div><div>In line with vascular hypothesis of systemic sclerosis (SSc), it is proposed that visceral Raynaud's phenomenon (RP)/endothelial dysfunction causes severe oxygen supply/consumption imbalance in internal organs, leading to visceral ischemic failure in early SSc, especially with cold environmental temperature (Te) and severe RP. There would also be a decrease in body thermogenesis and a decrease in heat loss caused by chronic visceral ischemia and by systemic vasculopathy, respectively. At any given time, these disorders could produce low core temperature (Tc). Hence, SSc is proposed as a candidate cause of secondary hypothermia. It is suggested that SSc could be an adaptive response in cold Te to systemic endothelial damage with secondary chronic visceral ischemia/slow metabolism. This pathophysiological mechanism is proposed in early visceral failure, prognosis, SSc phenotype according to ethnicity, and other manifestations. The impact of Te and Tc on SSc warrants further investigations.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 5","pages":"Article 501894"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry","authors":"Clementina López-Medina ,&nbsp;Lucía Otero-Varela ,&nbsp;Fernando Sánchez-Alonso ,&nbsp;Vega Jovaní ,&nbsp;Lorena Expósito-Pérez ,&nbsp;Sheila Melchor-Díaz ,&nbsp;Yanira Pérez-Vera ,&nbsp;Paula Pretel-Ruiz ,&nbsp;Javier Manero ,&nbsp;Antonio Mera-Varela ,&nbsp;Lourdes Mateo ,&nbsp;Dolores Ruiz-Montesino ,&nbsp;José Andrés Lorenzo-Martín ,&nbsp;Teresa Pedraz-Penalva ,&nbsp;Isabel Castrejón","doi":"10.1016/j.reuma.2025.501872","DOIUrl":"10.1016/j.reuma.2025.501872","url":null,"abstract":"<div><h3>Introduction</h3><div>Ixekizumab (IXE) is a selective interleukin 17A (IL-17A) monoclonal antibody approved for the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). Limited real-world data are available on its retention rate and effectiveness. The objective of this study was to assess the one-year retention rate of IXE in a real-world cohort of patients with axSpA and PsA and to identify potential predictive factors for drug retention.</div></div><div><h3>Method</h3><div>Prospective and observational study derived from BIOBADASER 3.0, a multicenter registry of advanced therapies including patients who have ever received IXE for PsA or axSpA. The one-year retention rate of the treatment in both diseases was evaluated using Kaplan–Meier curves and multivariable Cox regressions.</div></div><div><h3>Results</h3><div>A total of 335 patients ever exposed to IXE were included (PsA<!--> <!-->=<!--> <!-->250; axSpA<!--> <!-->=<!--> <!-->85). IXE was used as first-line treatment only in 5.3% of patients, and after TNFi in 94.7% of patients. In axSpA and PsA, drug survival at 12 months was 69.5% (95% CI 64.0–74.3), slightly higher in PsA (71.3% (95% CI 65.0–75.6)) versus axSpA (63.8% (95% CI 51.5–73.7)). The multivariable Cox regression models showed that female sex and longer disease duration were factors associated with IXE withdrawal in the whole population, while concomitant use of methotrexate reduced the risk of discontinuation.</div></div><div><h3>Conclusions</h3><div>In this real-world study, IXE showed an acceptable retention rate in patients with PsA and axSpA after one year of follow-up. Female sex and longer disease duration were associated with risk of withdrawal.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 5","pages":"Article 501872"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lupus nephritis in Mexican patients: Response to intensive therapy","authors":"Georgina Aguilera Barragán-Pickens ,&nbsp;David Herrera van-Oostdam ,&nbsp;Fedra Irazoque-Palazuelos ,&nbsp;Miguel Saavedra-Salinas ,&nbsp;Sergio Cerpa-Cruz ,&nbsp;Claudia Mendoza-Pinto ,&nbsp;Luis Valdez ,&nbsp;Enrique Cuevas Orta ,&nbsp;Eva Santillán-Guerrero ,&nbsp;Carlos Abud-Mendoza ,&nbsp;LUNPOS GROUP","doi":"10.1016/j.reuma.2025.501896","DOIUrl":"10.1016/j.reuma.2025.501896","url":null,"abstract":"<div><h3>Introduction</h3><div>lupus nephritis represents a challenge in treatment. In spite of intensive therapy, is common a sustained renal incomplete response.</div></div><div><h3>Objective</h3><div>To describe different responses to adequate/intensive treatment to lupus nephritis.</div></div><div><h3>Methods</h3><div>Observational retrospective study, including Mexican<!--> <!-->&gt;<!--> <!-->18 years old patients with lupus nephritis who visited tertiary rheumatology centers in several urban cities in Mexico. SLE was diagnosed according to 1997 ACR. The exclusion criteria were follow-up<!--> <!-->&lt;<!--> <!-->6 months and reduced GFR due to other comorbidities such as diabetes or other primary renal disease.</div></div><div><h3>Results</h3><div>We included 193 patients with a mean age of 34 years, 80% were women. Biopsy was available in 166 patients (86%): class IV in 42%, class III in 23%, the mean of activity and chronicity index were 6.4 and 2.6 respectively; class V represented 10.2%. The least frequent class was Class II (9%), and mixed classes (III or IV<!--> <!-->+<!--> <!-->V) accounted for 11%.</div><div>Cyclophosphamide (CYC) was used in 146 patients (76.6%), mycophenolate (MMF) in 144 and tacrolimus (TCR) in 28. In most cases, were used combination therapy.</div><div>Only 38 patients had a follow-up of less than 1 year; 16 (42%) had CR, 13 (34%) had NR, and 9 (23%) PR. 55% of patients with PR received a multitarget protocol, 75% of CR received the NIH protocol, and 61.5% of NR the NIH protocol.</div><div>Of patients followed up for more than a year (155), 35% had persistently inactive response, 24.5% were relapsing–remitting, 20% were chronically active, and 20% showed a mixed pattern.</div></div><div><h3>Conclusions</h3><div>Prevalence of persistent or intermittent activity patterns was high (64.5%). Most Mexican rheumatologists switched to more intensive treatment, adding a second or third drug.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 5","pages":"Article 501896"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144262870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: “Safety of biologic and synthetic targeted therapies in patients with immune-mediated diseases: Data from the BIOBADAGUAY registry”","authors":"Sarah Aijaz ,&nbsp;Raveen Muzaffer","doi":"10.1016/j.reuma.2025.501871","DOIUrl":"10.1016/j.reuma.2025.501871","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 4","pages":"Article 501871"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel imaging findings of masticatory muscle edema in dermatomyositis associated with ovarian cancer: A case report","authors":"Leonardo F. Freitas ,&nbsp;Márcio Luís Duarte ,&nbsp;Kevin J. Abrams","doi":"10.1016/j.reuma.2025.501857","DOIUrl":"10.1016/j.reuma.2025.501857","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 4","pages":"Article 501857"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Raoul Dufy: color y resiliencia en la lucha contra la artritis reumatoide","authors":"Fernando Canillas,&nbsp;Marta Canillas","doi":"10.1016/j.reuma.2025.501847","DOIUrl":"10.1016/j.reuma.2025.501847","url":null,"abstract":"<div><div>Raoul Dufy was born in 1877 in the city of Le Havre, France. He showed an early interest in painting and attended the École des Beaux Arts in Paris, where he was influenced by Impressionism and later by Fauvism and Cubism. He achieved a style of his own, marked by colour. His paintings depicted modern life, often with bright colours and energetic scenes of urban and social life. In 1935, he developed severe rheumatoid arthritis, which affected his hands and joints. Despite this, he continued to create art until his death. He underwent numerous medical treatments of the time. In 1950, he was invited to the United States to participate in initial ACTH and cortisone therapies and achieved a significant improvement. He returned to France, but died in 1953 at the age of 76 from an intestinal haemorrhage. His artistic legacy and his strength to face this disease are an inspiration for the future.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 4","pages":"Article 501847"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of kinesiophobia and physical activity levels in patients with fibromyalgia syndrome and chronic neck pain","authors":"Melek Aykut Selçuk ,&nbsp;Gülseren Demir Karakılıç ,&nbsp;Esra Mert ,&nbsp;Burcu Duyur Çakıt","doi":"10.1016/j.reuma.2025.501849","DOIUrl":"10.1016/j.reuma.2025.501849","url":null,"abstract":"<div><h3>Introduction</h3><div>We aimed to evaluate pain, kinesiophobia, physical activity, depression, disease severity and fatigue in patients with Fibromyalgia syndrome (FMS) and chronic neck pain (CNP) and healthy controls.</div></div><div><h3>Material and methods</h3><div>Fifty-two patients with FMS (group 1), 52 patients with CNP (group 2) and 52 healthy controls (group 3) were included in the study. Visual Analog Scale (VAS) was used to evaluate pain intensity and fatigue, Tampa Scale of Kinesiophobia (TSK) for kinesiophobia, Beck Depression Inventory (BDI) for depression, International Physical Activity Questionnaire (IPAQ) Short Form for physical activity level, Revised Fibromyalgia Impact Questionnaire (rFIQ) for functional status in FMS, and Neck Pain Disability Index (NPDI) for neck pain-related disability in patients with CNP.</div></div><div><h3>Results</h3><div>The mean age was similar in all three groups (42.96) and the ratio of female was higher in all three groups (94.2%, 90%, 88.6%). High level kinesiophobia was present in 86.6% of patients in group 1, 63.3% of patients in group 2 and 23.4% of participants in group 3 and statistically, kinesiophobia was more common in groups 1 than in groups 2 and 3 and in group 2 than in group 3. The rate of depression was 80%, 50% and 16% in groups 1, 2 and 3, respectively. In group 1, 70% of patients had low, 23.3% had moderate, and 6.6% had high physical activity levels. In group 2, 46.6% of patients had low, 36.6% had moderate, and 16.6% had high physical activity levels; in group 3, 23.3% had low, 53.4% had moderate, and 23.3% had high physical activity levels. There was a statistically significant difference in physical activity levels among the three groups and between group 1 and group 3 (<em>p</em> <!-->&lt;<!--> <!-->0.05), but no statistically significant difference was revealed in the remaining paired comparisons (<em>p</em> <!-->&gt;<!--> <!-->0.05). TSK score was positively and weakly correlated with VAS-pain (<em>p</em>:0.032, <em>r</em>:0.392) and rFIQ scores (<em>p</em>:0.025, <em>r</em>:0.408) in group 1, positively and strongly correlated with BDI scores (<em>p</em>:0.002, <em>r</em>:0.547) in group 1, and negatively and weakly correlated with physical activity levels (<em>p</em>:0.039, <em>r</em>: −0.378) in group 2.</div></div><div><h3>Conclusions</h3><div>The patients with group 1 and group 2 had higher levels of kinesiophobia, pain intensity, fatigue and a lower physical activity level than group 3.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 4","pages":"Article 501849"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sarcoidosis inducida por capecitabina en una paciente oncológica: presentación clínica con artritis","authors":"Yedra Usón-Rodríguez ,&nbsp;Fátima Mocha-Campillo ,&nbsp;Maialen Guerrero-Gómez ,&nbsp;Juan Lao-Romera ,&nbsp;Marina Soledad Moreno-García","doi":"10.1016/j.reuma.2025.501870","DOIUrl":"10.1016/j.reuma.2025.501870","url":null,"abstract":"<div><div>Sarcoidosis is a multisystemic granulomatous disease of uncertain etiology. Several drugs have been linked to the development of sarcoidosis or systemic granulomatous reactions indistinguishable from this disease. We present the clinical case of a patient diagnosed with breast cancer and undergoing treatment with capecitabine who, after developing systemic and musculoskeletal symptoms, was ultimately diagnosed with capecitabine-induced sarcoidosis.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 4","pages":"Article 501870"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mean corpuscular volume and red cell distribution width as predictors of methotrexate response in RA patients","authors":"Benitez Cristian Alejandro ,&nbsp;Gomez Ramiro Adrián ,&nbsp;Peón Claudia ,&nbsp;Alfaro María Agustina ,&nbsp;Federico Andrea ,&nbsp;Klimovsky Ezequiel ,&nbsp;Gamba María Julieta","doi":"10.1016/j.reuma.2025.501851","DOIUrl":"10.1016/j.reuma.2025.501851","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To correlate ΔRDW and ΔVCM (baseline and week 12) with the number of patients achieving remission or low disease activity by CDAI at week 24 after initiating MTX.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and methods&lt;/h3&gt;&lt;div&gt;Retro-prospective, analytical, and observational study in consecutive adult patients diagnosed with RA (ACR/EULAR 2010). Demographic data, clinical characteristics, personal history, initiated treatments, and VCM (fL) and RDW (%) at weeks 0, 4, 12, and 24 were evaluated. Safety data was recorded. Statistical analysis: descriptive analysis, Chi&lt;sup&gt;2&lt;/sup&gt; test or Fisher's exact test; Student's &lt;em&gt;T&lt;/em&gt;-test or Mann–Whitney; and ANOVA or Kruskal–Wallis. Lineal and/or multiple logistic regression.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;139 patients were included, of whom 109 completed the study requirements. 83.5% were women, median age (m) 50 years (IQR 39–60), with a median disease duration of 12 months (IQR 0–78). In the per-protocol analysis of 109 patients, the m ΔRDW between baseline and week 12 was 0.8 (IQR 0–2.4), and the m ΔVCM was 2.0 (IQR 0.1–4.4). No correlation was found between ΔRDW and CDAI at week 24 (Rho&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;−0.08; &lt;em&gt;p&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.416), but a statistically significant correlation was found between ΔVCM and CDAI at week 24 (Rho&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;−0.190; &lt;em&gt;p&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.048).&lt;/div&gt;&lt;div&gt;Results were analyzed by intention to treat for 139 patients. Between baseline and week 12, a m ΔRDW of 0.8 (IQR 0–2.4) and a m ΔVCM of 2.2 (IQR 0.2–4.5) were recorded. No correlation was found between ΔRDW and CDAI at week 24 (Rho&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;−0.073; &lt;em&gt;p&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.433), but a statistically significant correlation was found between ΔVCM and CDAI at week 24 (Rho&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;−0.217; &lt;em&gt;p&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.018). 64.2%, 39.4%, and 15.6% of patients achieved CDAI 50/70/85 responses at week 12, respectively, with no significant changes at week 24. Univariate and multivariate analysis identified that the only factor significantly associated with achieving CDAI 50 at week 24 was achieving such a response at week 12 (&lt;em&gt;p&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.001).&lt;/div&gt;&lt;div&gt;Safety evaluation showed that 68 patients (48.9%) experienced adverse events, with 20 events (14.4%) related to MTX. Only 5 (3.6%) were considered serious adverse events, all of them unrelated to treatment.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;This study revealed that an increase in red cell distribution width (RDW) and mean corpuscular volume (VCM) was associated with the initiation of MTX treatment. However, only a significant correlation was found between the change in VCM and RA activity measured by CDAI at week 24. Although ΔRDW did not show a significant association with RA activity, ΔVCM negatively correlated with CDAI at week 24. Additionally, a significant percentage of patients achieved a positive response at week 12, but there were no significant changes at we","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 4","pages":"Article 501851"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of electrocardiographic altered P wave dispersion and vascular endothelial growth factor in rheumatoid arthritis","authors":"Osmar Antonio Centurión ,&nbsp;Paloma de Abreu ,&nbsp;Gabriela Avila-Pedretti ,&nbsp;Sonia R. Cabrera ,&nbsp;María T. Martínez de Filártiga ,&nbsp;Astrid Paats ,&nbsp;Judith M. Torales ,&nbsp;Christian O. Chávez ,&nbsp;Carmen R. Montiel ,&nbsp;Laura B. García ,&nbsp;Karina E. Scavenius ,&nbsp;Rocío del Pilar Falcón ,&nbsp;Jose C. Candia ,&nbsp;Alfredo J. Meza ,&nbsp;Isabel Acosta-Colmán","doi":"10.1016/j.reuma.2025.501856","DOIUrl":"10.1016/j.reuma.2025.501856","url":null,"abstract":"<div><h3>Objectives</h3><div>Serum vascular endothelial growth factor (VEGF) levels correlate with structural alterations in Rheumatoid Arthritis (RA). Since P wave dispersion (PWD) is associated with atrial ischemic-related fibrotic changes, it was conceived that there may be a correlation between altered PWD and increased VEGF levels in RA.</div></div><div><h3>Methods</h3><div>In this prospective observational study, we evaluated patients with RA, and compared them to control subjects. PWD was considered as the difference between the maximum and minimum duration of the P wave. An altered PWD was considered one that had dispersion<!--> <!-->≥<!--> <!-->38<!--> <!-->ms. Measurements of VEGF serum levels were performed using enzyme-ligand, immunosorbent measurement ELISA kits.</div></div><div><h3>Results</h3><div>A total of 99 patients with RA, and 48 control subjects were evaluated. The PWD was 25.3<!--> <!-->±<!--> <!-->4.9<!--> <!-->ms in the control group vs. 57<!--> <!-->±<!--> <!-->14.9<!--> <!-->ms (<em>p</em> <!-->&lt;<!--> <!-->0.0001) in the RA group. No patient in the control group had altered PWD, while 94 (95%) patients in the RA group presented it (<em>p</em> <!-->&lt;<!--> <!-->0.0001). The value of VEGF in the control group was 15.2<!--> <!-->±<!--> <!-->15.1<!--> <!-->pg/ml vs 51.1<!--> <!-->±<!--> <!-->55.5<!--> <!-->pg/ml (<em>p</em> <!-->&lt;<!--> <!-->0.001) in RA. The value of VEGF in RA without altered PWD was 20<!--> <!-->±<!--> <!-->12<!--> <!-->pg/ml vs 56<!--> <!-->±<!--> <!-->57<!--> <!-->pg/ml in RA with altered PWD (<em>p</em> <!-->&lt;<!--> <!-->0.02). An elevated VEGF value had a specificity of 80%, and a positive predictive accuracy of 95% in predicting altered PWD in RA.</div></div><div><h3>Conclusions</h3><div>This study establishes for the first time that RA patients who possess significantly higher serum levels of VEGF have an altered PWD. The presence of an elevated VEGF serum value has a high specificity, and high positive predictive accuracy of the existence of altered PWD in RA.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 4","pages":"Article 501856"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}